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Abstract
Epidemiological studies describe estrogens as protectors in the development of 
colon cancer in postmenopausal women treated with hormone replacement therapy. 
However, the role of progesterone in colon cancer has been minimally studied and the 
results are controversial. For the above, the objective of this work was to determine 
the hormonal regulation exerted by natural ovarian steroids on proliferation and 
apoptosis in an experimental model of colon cancer in ovariectomized rats treated 
with 17-beta estradiol and progesterone. Sprague–Dawley rats were exposed to the 
carcinogen 1,2-dimethylhydrazine to induce colon tumors. Thirty days later, the rats 
were ovariectomized and treated with estradiol (60 μg/kg), progesterone (10 mg/kg), 
estradiol plus progesterone (60 μg/kg and 10 mg/kg) or vehicle. We observed no significant 
differences in colon cancer incidence and tumor multiplicity between the groups. 
Nevertheless, we observed a decrease in PCNA expression and a greater number of 
apoptotic index, higher expression of caspase 3, cleaved PARP and cleaved caspase 8 in 
tumors, confirming the activation of the extrinsic pathway of apoptosis by the combined 
treatment. In addition, we observed a higher expression of estrogen receptor beta in 
these tumors. We conclude that the action of both hormones, estradiol and progesterone, 
is necessary to reduce proliferation and increase apoptosis in colon tumors, probably 
through estrogen receptor beta activation.
Introduction
Colorectal cancer (CRC) is the third most common cancer 
and one of the tumors with the highest incidence and 
mortality worldwide, with an increasing projection for the 
coming decades. CRC incidence and mortality rates are 
30 and 40%, respectively, higher in men than in women 
(1). Since the Women’s Health Initiative in 1991 (2), and 
several epidemiological studies, the ovarian steroids were 
considered protectors against the development of CRC. 
Different studies in animal models showed a lower risk 
of CRC in the presence of estrogens (3, 4). Nevertheless, 
some studies indicate that, once the disease has developed, 
estrogens inhibit cell proliferation, while others suggest 
they induce mitogenic effects (5). The oncogenic effects of 
estrogens have been widely studied in breast and ovarian 
cancer, but little is known about its action in colon cancer 
(6). Regarding their receptors, it is known that estrogen 
receptor beta (ERB) is the predominant isoform in the 
colon (7, 8, 9) and that its expression is lost during the 
progression of colon cancer, suggesting that it would 
play an important role in the progression of this disease 
(10, 11). Recent studies involving tumor samples from 
patients with CRC have shown that elevated expression 
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of ERB is associated with a better prognosis, supporting 
its role as a possible target for chemoprevention (12, 13). 
Experiments carried out on ERB-knockout mice conclude 
that its loss leads to an increase in proliferation, loss of 
differentiation and decrease in apoptosis in the colon 
epithelium, suggesting an important role of this receptor 
in the normal organization and structural maintenance 
of the colon (11). Moreover, colon cancer cell lines have 
been reported to express mostly ERB after stimulation 
with estradiol (10–1000 nmol/L), with an induction 
of apoptosis dependent on the dose (6). With respect 
to estrogen receptor alpha (ERA), it has been reported 
that its expression is minimal in normal colon and in 
colon cancer cells (7, 14). Therefore, most of the studies 
demonstrate that the protective effects of estradiol in 
colon carcinogenesis are carried out by the ERB.
In addition to the known effects of estrogens on colon 
tumorigenesis, we should also consider progesterone 
(P4) as another of the ovarian steroids involved in this 
disease. There are some studies reporting the absence of 
the expression of progesterone receptor (PR) in colon 
tumors and no effect of progestins on carcinogenesis 
in animal models (15). However, other studies report 
the implication of P4. For example, the expression of 
PR increases in the order of normal colon-adenoma-
adenocarcinoma, supporting its role on this disease (16). 
Furthermore, some studies propose synthetic progestins 
as chemopreventive agents in colon cancer (17), but little 
is known about the role of natural P4. The cellular effects 
of P4 in colonocytes have been minimally studied, and 
the relationship between P4 and ER is not yet elucidated 
(18). Thus, the objective of this work was to determine 
the hormonal regulation exerted by natural ovarian 
steroids on proliferation and apoptosis in an experimental 
model of colon cancer in ovariectomized rats treated with 
17-beta estradiol and P4.
Materials and methods
Animals
Virgin Sprague–Dawley female rats were kept in a light- 
(lights on 06.00–20.00 h) and temperature-controlled 
room (22–24°C) in our animal facility. Rat chow (Cargill, 
Córdoba, Argentina) and tap water were available 
ad libitum.
Animal maintenance and handling were performed 
according to the NIH guide for the Care and Use of 
Laboratory Animals (NIH publication no. 86-23, revised 
1991) and the UK requirements for ethics of animal 
experimentation (Animals Scientific Procedures, Act 
1986). All the experimental procedures were approved by 
the Animal and Ethics Committee (CICUAL) of the School 
of Medicine of the National University of Cuyo, Mendoza, 
Argentina (0011463/2011).
Experimental protocols
To induce colon cancer, 45-day-old rats (approximately 
weighting 170 g) were treated subcutaneously once a week 
with 1,2-dimethylhydrazine (DMH, 21 mg/kg; Sigma), for 
20  weeks as previously described (19, 20). Four weeks 
after the first DMH dose, the rats were anesthetized by 
an intraperitoneal injection of ketamine-xylazine (45 and 
10 mg/kg) and were ovariectomized as previously described 
(21). In order to study the effects of the ovarian steroids on 
colon carcinogenesis, they started receiving subcutaneous 
injections twice a week with 17-beta estradiol (E2 group, 
60 μg/kg, N = 13; Sigma), progesterone (P4 group, 10 mg/kg, 
N = 14; Sigma), E2 and P4 (E2 + P4 group, 60 μg/kg and 
10 mg/kg, respectively, N = 13) or vehicle (V group, vegetal 
oil, N = 10) until they were killed. All the animals were 
periodically controlled for symptoms, irrespective of the 
treatment. The same observer checked weekly the rats in 
the same way, looking for loss of weight, diarrhea or any 
sign of distress.
The incidence of colon cancer was calculated as 
the percentage of rats that presented tumors within the 
period studied. The rats were decapitated the day they 
were expected to receive the following hormonal dose. 
In consequence, they were killed 84 h after the last 
injection. Since the rats were killed when they exhibited 
symptoms of tumor presence, we compared the day of 
killing in order to have a parameter related to latency, 
and we expressed it as latency of appearance of evident 
symptoms. The animals without any symptom were killed 
at day 270 from the first DMH dose. Trunk blood samples 
were collected and allowed to clot at room temperature. 
Serum was separated and stored at −20°C until assayed for 
hormone determinations. Immediately after decapitation, 
a piece of the tumor was removed for histopathological, 
immunohistochemical and Western blot (WB) analysis.
Hormone determinations
To determine the serum levels of estradiol and 
progesterone, the specific commercial Coat-A-Count kits 
(TKE21 and TKPG1; Siemens Healthcare Diagnostics Inc.) 
were used according to the manufacturer’s instructions. 
A total of 100 µL of the calibrators or 100 µL of sera were 
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added to the precoated tubes in duplicate. One milliliter 
of 125I estradiol or 125I progesterone was added to each tube 
and incubated for 3 h at room temperature. The content of 
the tubes was aspirated and counted for 1 min in a gamma 
counter. Assay sensitivity was 8 pg/mL for estradiol and 
0.02 ng/mL for progesterone. The inter- and intra-assay 
coefficients of variation were <10% for both hormones.
Tumor histology
After decapitation, a small piece of tumor of each rat 
was fixed in 4% v/v formaldehyde for 24 h, dehydrated 
in ethanol and embedded in paraffin wax. Sections of 
3–5 µm were cut in a HYRAX M 25 Rotary microtome 
(Zeiss) and stained with hematoxylin–eosin (H&E) for 
the analysis under the optic microscope. The tumor grade 
and type, the inflammation grade, fibrosis, necrosis and 
mitotic and apoptotic index were defined. The number 
of mitotic figures and apoptotic bodies present in the 
tumor cells in ten fields was counted under microscope at 
a magnification of 400×. The mitotic and apoptotic index 
was calculated dividing the number of mitotic figures by 
the number of apoptotic bodies for each tumor.
Immunohistochemistry
Sections of 3–5 μm from each tumor underwent an antigen 
retrieval protocol using heat (40 min in citrate buffer 
0.01 M, pH 6.0). After two washes with distilled water, the 
endogen peroxidase was blocked with 0.1% w/v sodium 
azide for 30 min. The nonspecific binding sites were 
blocked with 10% w/v of skim milk. The primary antibodies 
used were PCNA (M0879, 1:600 dilution; Dako), caspase 
3 (ab4051, 1:400 dilution; Abcam), ERA (ab32063, 1:200 
dilution; Abcam), ERB (ab3577, 1:750 dilution; Abcam) 
and PR (sc-539, 1:100 dilution; Santa Cruz Biotechnology 
Inc.). The antibodies were incubated overnight at 4°C in 
humidity chambers. A commercial kit to detect mouse 
and rabbit antibodies was used (Dako EnVision Systems, 
horseradish peroxidase, diaminobenzidine; Dako). Slides 
were lightly counterstained with hematoxylin to reveal 
nuclei, examined and photographed. The immunostaining 
was evaluated considering the extent, intensity and 
localization of immunostaining independently by two 
experienced researchers blinded regarding the hormone 
treatments, and a few conflicting scores were resolved by 
consensus. The intensity score was measured as follows: 
0 = no staining, 1 = weak staining, 2 = moderate staining, 
3 = strong staining; and a proportion score: 0 = no staining, 
1 = staining less than 10% of the tumor cells, 2 = between 
11 and 33%, 3 = between 34 and 65%, 4 = greater than 
66%. The images were taken with a Nikon Eclipse E200 
microscope (Nikon) equipped with a digital micrometrics 
SE High Quality camera (Accu-Scope, Commak, NY, USA) 
at a magnification of 400×.
Protein isolation and WB
Total proteins in 200 mg from each tumor were isolated 
by mechanical homogenization with two volumes of 
homogenization buffer (50 mM Tris, pH 7.5, 250 mM 
sucrose, 10 mM benzamidine, 10 mM NaF, 5 mM sodium 
pyrophosphate, 20 mM glycerophosphate, 1 mM sodium 
orthovanadate, 1 mM PMSF, 10 mM p-nitrophenylphosphate, 
and aprotinin, leupeptin and pepstatin at 2 mg/L) in an 
ice bath. The homogenate was centrifuged at 12,500 g 
for 30 min and the supernatant was separated and frozen 
in several aliquots at −80°C until used. Proteins were 
quantified using the Micro BCA Protein Assay Kit (Thermo 
Scientific), and boiled for 5 min in loading buffer. Eighty 
micrograms of proteins were separated by SDS-PAGE and 
transferred to PVDF membranes (Immobilon-P, Merck 
Millipore). After rinsing and blocking with 2% w/v 
BSA (Sigma), the membranes were probed overnight at 
4°C with antibodies targeting caspase 3 (ab4051, 1:500 
dilution; Abcam), cleaved PARP (ab32064, 1:2000 dilution; 
Abcam), caspase 8 (ab25901, 1:1000 dilution; Abcam), ERA 
(ab32063, 1:2500 dilution; Abcam), ERB (ab3577, 1:3000 
dilution; Abcam), PR (sc-539, 1:200 dilution; Santa Cruz 
Biotechnology Inc.) and B-actin (sc-47778, 1:3000 dilution; 
Santa Cruz Biotechnology Inc.). After a new rinsing, the 
membranes were probed with horseradish peroxidase-
conjugated secondary antibodies anti-rabbit (sc-2004, 
1:2000 dilution; Santa Cruz Biotechnology Inc.) or anti-
mouse (sc-2005, 1:2000 dilution; Santa Cruz Biotechnology 
Inc.) for 90 min at room temperature. The membranes were 
rinsed and the bands were detected by chemiluminescence 
(ECLTM; Amersham) using a ChemiDoc XRS + System with 
Image Lab Software from Bio-Rad and then quantified by 
densitometry using digital image processing by the NIH 
ImageJ 1.6 freeware program. Quantitative analysis of the 
different protein levels was performed by determining the 
ratio between the specific protein and B-actin levels by 
densitometry.
Expression of the ESR1, ESR2 and PGR genes in  
human colon adenocarcinomas
Tumors from The Cancer Genome Atlas (TCGA) colon 
cancer database (https://portal.gdc.cancer.gov accessed 
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-18-0374
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 01/28/2021 08:34:44PM
via free access





on November 26, 2018) were evaluated. Data was 
programmatically downloaded using R TCGAbiolinks 
package. Four hundred seventy-six primary tumors 
were obtained and patients were classified according to 
their gender (males N = 252 or females N = 224). Females 
were further divided according to their age: greater than 
50  years (N = 191) or less than 50  years (N = 33) at the 
time of diagnosis. Raw RNA-Seq expression counts were 
used and normalized using Voom transformation from R 
Limma package (https://genomebiology.biomedcentral.
com/articles/10.1186/gb-2014-15-2-r29 accessed on 
November 26, 2018). Transformed gene expression 
distribution was depicted using boxplots and expression 
correlation between the three genes was evaluated using 
Pearson’s correlation coefficient with its corresponding 
P value. The direction of the relation was calculated using 
simple linear regression and depicted as a straight line 
with a slope in a scatterplot.
Statistical analysis
Values are given as means ± s.e.m. of 10–14 animals per 
group. All statistical analyses were performed using 
GraphPad Prism 5.01 software (GraphPad Software Inc.). 
The data were analyzed by ANOVA I, with subsequent 
analysis of Newman–Keuls for the parametric variables, 
and the Kruskal–Wallis and Dunn’s for the nonparametric 
variables. The incidence percentages were analyzed by 
Fisher’s test. Differences between means were considered 
significant at the P < 0.05 level.
Results
The doses administered of 17-beta estradiol and 
progesterone reach values within the 
physiological range
To confirm that the dose administered of the ovarian 
steroids was within the normal levels, we measured the 
concentration of estradiol and progesterone on the sera 
of the rats at the end of the experiment. We observed 
that the group of rats treated with E2 and E2 + P4 reached 
the highest values of estradiol (P < 0.01), with an average 
near to 50 pg/mL (Fig.  1A). On the other hand, the 
levels of progesterone were higher in the groups P4 and 
E2 + P4, with an average of 20 ng/mL (Fig. 1B; P < 0.01 and 
P < 0.001). These levels of ovarian steroids are within the 
physiological range that has been described for Sprague–
Dawley rats in the estrous cycle (23).
Hormone treatment does not affect colon cancer 
incidence and tumor multiplicity, and retards the 
appearance of symptoms
To study the effect of ovarian steroids on the development 
of colon tumors, we analyzed several aspects including 
the tumor incidence. Rats treated with P4 or V presented 
an incidence of 93 and 90%, respectively (Fig.  2A). The 
groups treated with E2 or E2 + P4 reached an incidence 
of 85%. When performing the statistical analysis, no 
significant differences were found among these results. 
Also, no significant differences were observed in the 
number of tumors developed in each rat with regard to 
the different treatments (Fig. 2B).
A higher latency of appearance of evident symptoms 
was observed for group E2 + P4 with respect to the group 
treated only with P4 (Fig. 2C; P < 0.01), which is probably 
related to a higher latency in the appearance of tumors. 
Most of the tumors were classified as adenocarcinomas of 
different grades.
Figure 1
Levels of estradiol (A) and progesterone (B) in sera of Sprague–Dawley 
rats treated with different hormones. The rats treated with V, E2, P4 or 
E2 + P4 were killed at the end of the experiment and the hormone levels 
were determined in the sera by radioimmunoassay. **P < 0.01 and *** 
P < 0.001 compared to the other groups. The data were analyzed by 
ANOVA I with post analysis of Newman–Keuls.
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Treatment with E2 + P4 reduces the mitotic/apoptotic 
index in colon tumors
To study the influence of ovarian steroids on tumor 
progression, the relationship between the mitotic and 
apoptotic index was calculated dividing the mitotic figures 
by the apoptotic bodies for each tumor. We observed that 
treatment with only E2 significantly increased mitosis 
in tumors compared to the group treated with V (Fig. 3A; 
P < 0.05). Regarding apoptosis, the combined treatment with 
E2 + P4 significantly increased (Fig. 3B; P < 0.05) the number 
of apoptotic bodies with respect to the other groups. The 
relation between the mitotic and apoptotic index decreased 
in the E2 + P4 group compared to E2 alone (Fig. 3C). Therefore, 
treatment with only E2 would induce proliferation whereas 
E2 + P4 would promote apoptosis in colon tumors.
Figure 2
Incidence, tumor multiplicity and latency of appearance of symptoms in 
Sprague–Dawley rats treated with different hormones. (A) Tumor incidence. 
The incidence was expressed as a percentage of rats that developed colon 
tumors. The data were compared with Fisher’s test. (B) Tumor multiplicity. 
The number of tumors developed was counted for each rat and the average 
obtained for each experimental group was graphed. The data were analyzed 
by ANOVA I with subsequent Newman–Keuls analysis. (C) Latency of 
appearance of symptoms. The animals were killed when they presented 
diarrhea or weight loss, symptoms that were taken as a parameter of tumor 
presence. For those who did not present symptoms, the 270th day from the 
administration of DMH was taken as the end of the experiment. **P < 0.01 
between the groups indicated with the bar. The data were analyzed by 
ANOVA I with subsequent analysis of Newman–Keuls.
Figure 3
Mitotic and apoptotic indices in colon tumors from Sprague–Dawley rats. 
(A) The mitotic index was calculated as number of mitotic figures present 
in ten fields analyzed by microscopy at 400×. (B) The apoptotic index was 
calculated as quantity of apoptotic bodies present in ten fields analyzed 
by microscopy at 400×. (C) Relationship between the mitotic and 
apoptotic index (M/A). *P < 0.05 between the groups indicated by the bars 
in (A) and (C), and respect to other groups in (B). The data were analyzed 
by ANOVA I with subsequent analysis of Newman–Keuls.
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Treatment with E2 + P4 decreases cell proliferation in 
colon tumors
To study further the effect of ovarian steroids on tumor 
cell proliferation, we analyzed the expression of PCNA by 
immunohistochemistry (IHC). We observed that the tumors 
from group E2 + P4 showed a lower expression of PCNA 
compared to the other groups (Fig. 4; P < 0.01), indicating 
an antiproliferative effect when both hormones are present.
E2 + P4 treatment increases cell apoptosis in 
colon tumors
Since we observed an increase in cell apoptosis due to the 
combined treatment of E2 + P4, we analyzed the expression 
of proteins associated with this form of programmed cell 
death. Figure  5 shows the expression of caspase 3 and 
cleaved PARP in tumors from the different groups. The 
treatment with E2 + P4 increased the expression of total 
caspase 3 compared to the other groups, demonstrated 
by IHC and WB (Fig. 5A, B and C, P < 0.01 and P < 0.001). 
Tumors from the V group showed a decreased expression 
of cleaved caspase 3 compared to the other groups (Fig. 5D; 
P < 0.05). We also observed an augmented expression of 
cleaved PARP in the E2 + P4 group (Fig. 5E; P < 0.001). These 
results confirm the activation of the apoptotic process by 
the treatment with E2 + P4.
E2 + P4 treatment induces apoptosis through the 
extrinsic pathway
To elucidate the pathway involved in the activation of 
apoptosis in the tumors from the E2 + P4 group, we analyzed 
the proteins of the BCL2 family and caspases 8 and 9. No 
differences were observed in the expression of BAX, BCL2 
and cleaved caspase 9 (data not shown), suggesting that the 
intrinsic pathway is not involved in the apoptosis produced 
by E2 + P4 in colon tumors. Therefore, the expression of 
cleaved caspase 8 was analyzed by WB to determine if the 
apoptosis observed was driven by the extrinsic pathway. 
The results showed a significant increase (Fig. 6; P < 0.01) in 
the expression of cleaved caspase 8 in tumors from E2 + P4 
compared to the other groups. Therefore, the extrinsic 
pathway may be involved in the apoptotic process produced 
by the treatment with E2 + P4 in colon tumors.
E2 + P4 treatment increases the expression of ERB
To analyze the status of hormone receptors responsible 
for the action of the ovarian steroids, the expressions of 
ERA and ERB were quantified by IHC and WB. IHC did 
not show differences in the expression and localization 
of both receptors between the different treatments (data 
not shown). By WB, we observed an increase in ERA 
expression in the E2 group compared to the other groups 
(Fig. 7A; P < 0.01). As for the ERB, we observed a consistent 
increase in the E2 + P4 group compared to the other groups 
(Fig. 7B; P < 0.01). When we analyzed the ratio between the 
two receptor isoforms, a lower ratio (Fig. 7C; P < 0.05) was 
observed for tumors from combined treatment compared 
to the other groups.
Treatment with E2 induces the expression of PR
Since one of the most conspicuous effects of E2 is to 
induce the expression of the PR (24, 25), we analyzed by 
Figure 4
Expression of PCNA in colon tumors from Sprague–Dawley rats. The 
expression of this proliferation marker was evaluated by 
immunohistochemistry. (A) The score of immunostaining was calculated 
adding the percentage (0 = 0%; 1 ≤ 10%; 2 = 10–33%; 3 = 34–65%, 4 ≥ 66%) 
of tumor cells stained and the intensity (1 = weak, 2 = moderate, 3 = severe) 
of expression. (B) Representative microphotographs (400×) of PCNA 
immunostaining in colon tumors from rats treated with V, E2, P4 and 
E2 + P4. Black scale bar represents 50 μm. **P < 0.01 compared to the other 
groups. The scores were analyzed by the Kruskal–Wallis and Dunn’s test.
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IHC PR expression to assess for the action of E2 on the 
tumors. On the one hand, we observed that the treatment 
with E2 increased PR score compared to the other groups 
(Fig. 8; P < 0.001). On the other hand, treatment with P4 
decreased its expression compared to all groups (P < 0.05). 
The receptor was located both in cytoplasm and nucleus 
in all treatments. No differences were observed between 
the groups in the expression of the receptor isoforms 
determined by WB (data not shown).
ESR1 expression correlates with ESR2 and PGR 
expressions in human colon cancer
To compare the results obtained in our animal model with 
human colon tumors, we performed a gene expression 
analysis including all colon cancers from the TCGA 
COAD cohort. We discriminated tumors from men 
(M) and women over 50  years old (postM, considered 
postmenopausal women), and women under 50 years old 
(preM representing premenopausal women). We did not 
find any change in the levels of expression of the three 
steroid receptor genes between the groups. However, we 
found a strong correlation between the expression of 
ESR1 and PGR in preM (P < 0.01) and in M and postM 
(P < 2.2 × 10−16) (Fig.  9A). Moreover, ESR2 expression 
correlated with PGR expression in both M and postM 
groups (P < 4 × 10−6) (Fig.  9B). Additionally, a significant 
Figure 5
Expression of caspase 3 and cleaved PARP in colon tumors from Sprague–Dawley rats. Total caspase 3 expression was measured by IHC and the cleaved 
form was determined by WB. (A) The score of immunostaining was calculated adding the percentage (0 = 0%; 1 ≤ 10%; 2 = 10–33%; 3 = 34–65%, 4 ≥ 66%) 
of tumor cells stained and the intensity (1 = weak, 2 = moderate, 3 = severe) of expression. (B) Representative microphotographs (400×) of total caspase 3 
immunostaining in colon tumors from rats treated with V, E2, P4 and E2 + P4. Black scale bar represents 50 μm. (C) Expression of total caspase 3 in colon 
tumors evaluated by WB. (D) Expression of cleaved caspase 3 in colon tumors evaluated by WB. (E) Expression of cleaved PARP evaluated by WB. The 
bands were normalized against beta actin. *P < 0.05, **P < 0.01, ***P < 0.001, compared to the other groups. WB data were analyzed by ANOVA I with 
subsequent analysis of Newman–Keuls and the immunohistochemical scores were analyzed by the Kruskal–Wallis and Dunn’s test.
Figure 6
Expression of cleaved caspase 8 in colon tumors from Sprague–Dawley 
rats. The expression was measured by WB. The bands were normalized 
against beta actin. **P < 0.01 compared to the other groups. The data 
were analyzed by ANOVA I with subsequent analysis of Newman–Keuls.
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correlation between ESR1 and ESR2 was found in the M 
and postM groups (P < 2 × 10−8) (Fig. 9C).
Discussion
In the present study we used the carcinogen DMH to 
develop the experimental model of colon cancer. This 
drug has been widely used to induce adenocarcinoma 
of colon and rectum in rodents with high incidence and 
specificity (19, 26, 27). The histopathology of tumors 
developed with this carcinogen is similar to that observed 
for sporadic colon tumors in humans (28, 29) and is a 
highly versatile model for studies of chemoprevention, 
genetics and biology of colon cancer (30). Coincidentally, 
the tumors developed in our study were similar to those 
observed in human carcinogenesis. At the same time, the 
treatment with DMH produced a high tumor incidence 
in all groups. The lack of differences in incidence may 
be due to the potent effect of DMH which could not be 
reversed by any of our hormonal treatments. In human 
epidemiological studies, ovarian steroids have a protective 
effect on CRC, which varies between 20 and 40% (31, 
32). However, women who had received the therapy 
when they were diagnosed with CRC presented a more 
advanced stage in the disease. Therefore, although the 
estrogens are initially protective, once the CRC has been 
developed exogenous estrogens increase their growth (4). 
In a meta-analysis carried out with data published up to 
2010, the authors concluded that only a few studies had 
examined the associations between estrogen therapy vs 
combined therapy (estrogens plus progestins) and CRC 
(33). They also concluded that the use of combined 
therapy significantly reduced the risk of CRC, while 
the use of only estrogen produces more variable effects. 
The evidence of a possible differential risk associated with 
cyclic vs continuous combination therapy or depending 
on the administration routes is scarce (34). Some in 
vivo studies have indicated that estrogens inhibit the 
proliferation of CRC (5), while others suggest that they 
cause mitogenic effects (4). These controversies may be 
due to the differences in the experimental models in 
terms of initiation of therapy (before or after carcinogenic 
induction), types and doses of the steroids used, 
duration of the experiment, among others. In addition, 
our criterion to kill the animals was the appearance of 
symptoms compatible with the presence of tumors, such 
as the presence of diarrhea or weight loss. The latency of 
the appearance of symptoms was shorter after treatment 
with P4 compared to E2 + P4. That result might be due to a 
more evident symptomatology of the animals more than 
to a shortening of latency of tumor development. In fact, 
the location of the tumors was mainly in the distal colon 
of rats treated with P4 alone, different to the other groups. 
Besides, we found no significant difference in multiplicity. 
This observation may be due to the limitations of the 
animal model, the carcinogen used and the time of the 
killing.
Additionally, the mitotic index was higher in tumors 
from the E2 group compared to the V group. This effect 
was reversed by the combined treatment with P4. When 
we analyzed the apoptotic index, we found a decrease by 
the E2 + P4 treatment compared to the other groups. The 
augmented mitosis induced by E2 alone and the diminished 
apoptosis due to the combined treatment makes the 
mitotic and apoptotic indices ratio be significantly lower 
after E2 + P4 treatment. This observation was confirmed by 
a reduction in the expression of PCNA and an increased 
expression of total caspase 3 and its cleaved form. In 
addition, the E2 + P4 treatment augmented the expression 
Figure 7
Expression of estrogen receptor isoforms in colon tumors from Sprague–Dawley rats. The A (A) and B (B) isoforms from ER were evaluated by WB. The 
bands were normalized against beta actin. (C) Ratio between the expression of A and B isoforms of ER in each tumor. *P < 0.05 and **P < 0.01 compared 
to the other groups. The data were analyzed by ANOVA I with subsequent analysis of Newman–Keuls.
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of cleaved PARP and cleaved caspase 8, but did not modify 
the expression of BAX, BCL2 and caspase 9. Taken together 
all these results indicate that the apoptotic effect produced 
by the combined treatment of E2 + P4 on tumors is mainly 
driven through the extrinsic pathway. These results are 
in concordance with previous studies describing that the 
effects produced by P4 are opposite to those of E2 (18). 
In addition, there are also studies showing that estrogen-
only hormone replacement therapy does not produce 
changes in the prevalence or survival after developing 
colon cancer in women. The authors postulate that P4 
is necessary for protection against this type of cancer 
because of the modulation that exerts on the effects of 
estrogens on carcinogenesis (16).
On the other hand, there are controversial results 
regarding the expression of ERA in the colon (35, 
36). Using IHC no expression of ERA in samples from 
patients with CRC has been reported (37, 38). However, 
other studies show the expression of ERA in CRC, but at 
very low levels compared to the B isoform (3, 16). This 
controversy may be due to changes in the way samples 
were processed, the method or antibodies used, or the 
level of staining to consider a sample positive (39). In the 
present study, we observed an increase in the expression 
of ERA by the treatment with E2 and a decrease by E2 + P4 
administration. The higher expression of ERA produced 
in tumors by E2 can explain the effects observed on 
proliferation and the mitotic and apoptotic index. The 
activation of ERA is known to activate proliferation in 
epithelial cells, thus promoting carcinogenesis (40). Also, 
E2 can activate the G protein-coupled estrogen receptor 
(GPER), which has been described to increase proliferation 
in CRC (41, 42). We observed that the treatment with P4 
reduces ERA expression and this effect is enhanced when 
both hormones are present. Recently, Mohammed et  al. 
reported that P4 promotes direct interaction between its 
receptor and the ERA in breast cancer, which redirects 
the transcriptional activity of ERA, blocking proliferative 
actions caused by E2 alone (43). This should be one of 
the mechanisms involved in the decrease of the mitotic 
and apoptotic index induced by P4 in rats receiving 
also E2. Still, previous studies have postulated the loss 
of ERB in colon cancer progression with an increase in 
the expression of ERA, which would relate this receptor 
with a more invasive profile (44). Another study has 
reported that soy and estrone protect mice from the 
development of colon cancer even when they do not 
express ERA, suggesting that this isoform is not necessary 
to mediate the protective effects of estrogens in colon 
cancer (45). Therefore, although there are several reports 
on the presence of ERA in the colon, the signaling of 
estrogens is mediated predominantly through the ERB 
(46). We observed a low expression of ERB in tumors from 
groups treated with E2 or P4, while its expression was 
significantly augmented by the combined treatment of 
E2 + P4. Consequently, the ratio ERA/ERB was significantly 
decreased by the combined treatment. The proapoptotic 
effects observed by the combined treatment are related to 
the increase of the ERB expression. The antiproliferative 
and proapoptotic role of ERB in colon tumors have been 
described, and it is believed that those effects may be due 
Figure 8
Expression of progesterone receptor in colon tumors from Sprague–
Dawley rats. The expression of PR was measured by IHC. (A) The score of 
immunostaining was calculated adding the percentage (0 = 0%; 1 ≤ 10%; 
2 = 10–33%; 3 = 34–65%, 4 ≥ 66% of tumor cells stained) and the intensity 
(1 = weak, 2 = moderate, 3 = severe) of expression. (B) Representative 
microphotographs (400×) of PR immunostaining in colon tumors from 
rats treated with V, E2, P4 and E2 + P4. Black scale bar represents 50 μm. 
An insert has been included for better cell localization display. *P < 0.05 
and ***P < 0.001 compared to the other groups. The data were analyzed 
by the Kruskal–Wallis and Dunn’s test.
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to the combination of several events such as regulation of 
the cell cycle, decrease in the expression of oncogenes such 
as MYC and MYB, regulation of the anti-inflammatory 
response and an increase in DNA repair capacity (47). The 
loss of ERB expression in the normal colon produces a 
greater risk of suffering cancer and also, once the disease 
has developed, a lower expression is associated with a 
poor survival in patients (13, 48).
Finally, regarding the PRs, there are some studies 
that report the absence of PR expression in colon 
tumors and no effect of progestins on carcinogenesis in 
animal models (15). However, other studies detect the 
implication of P4, where the expression of PR increases 
in the order of normal colon-adenoma-adenocarcinoma, 
demonstrating a role for this receptor in the disease 
(16). In the present study we observed a high expression 
of PR in colon tumors due to treatment with E2 and a 
low expression in the group treated with P4 only. No 
changes were observed when the A and B isoforms were 
quantified separately. From these results we conclude 
that the PR seems to be regulated negatively by its ligand, 
unlike estrogen receptors that show both self-induced as 
self-repression. In uterine cells, ERs bound to E2 increase 
the expression of PR. It seems that in colon tumors this 
mechanism of regulation remains unchanged. Most of 
the literature on P4 or progesterone-like compounds is 
contradictory because the effects of synthetic progestins 
are different than those of natural progesterone. The 
difference in chemical structure is profound and results in 
different actions at the cell level (49). That may account 
for the controversy in the bibliography, which makes 
difficult to compare results from distinct studies. Thus, 
different progestins can be associated with different types 
of estrogens and different administration regimes (50).
In order to compare the results obtained in our 
animal model with human colon tumors, we performed 
a gene expression analysis search including all colon 
cancers from the TCGA COAD cohort. We can conclude 
that there is a strong correlation between the expression 
of ESR1, ESR2 and PGR. In the case of ESR2, the correlation 
with PGR is not statistically significant in the group of 
premenopausal women. We would expect to see a positive 
Figure 9
ESR1, ESR2 and PGR expression levels in colon tumors from the TCGA COAD cohort. (A) Correlation between ESR1 and PGR expressions. (B) Correlation 
between ESR2 and PGR expressions. (C) Correlation between ESR1 and ESR2 expressions. (D) Levels of expression of ESR1, ESR2 and PGR in colon tumors. 
Transformed gene expression correlation between the three genes was evaluated using Pearson´s correlation coefficient with its corresponding P value. 
The direction of the relation was calculated using simple linear regression and depicted as a straight line with a slope in a scatterplot.
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correlation in this particular case, since in our animal 
model the presence of ovarian steroids produces an 
increase in the ERB at protein level. Since these results 
are obtained measuring the mRNA levels, the expression 
of proteins could be changed due to posttranscriptional 
regulation. Our results from the TCGA COAD cohort 
suggest a role for ovarian hormone receptors in human 
colon carcinogenesis.
In conclusion, we demonstrated that the presence of 
natural ovarian steroids is necessary to observe protective 
effects on colon cancer. Consequently, to study the effect 
of P4 on the development of colon cancer is necessary since 
it is a hormone present in the early stages of the disease 
in women at childbearing age. Moreover, the number 
of postmenopausal women using natural progesterone 
instead of synthetic progestins in hormone replacement 
therapy is increasing. Therefore, the mechanism of action 
by which both hormones, E2 and P4, contribute to the 
proapoptotic effect observed in colon tumors remains to 
be elucidated.
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